Effects of tetrahydroxystilbene glucoside on mouse liver cytochrome P450 enzyme expressions

Xenobiotica

Volumn 45, Issue 4, 2015, Pages 279-285

  Wang, Yan Ying ^a   Yang, Jun ^a   Liu, Hang ^a   Lin, Feng Qin ^a   Shi, Jing Shan ^a   Zhang, Feng ^a  

^a ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

Cytochrome P450 enzyme; mouse liver; protein expression; tetrahydroxystilbene glucoside; transcription factors

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A11; GLUCOSIDE; LIVER PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TETRAHYDROXYSTILBENE GLUCOSIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AHR; TRANSCRIPTION FACTOR PXR; UNCLASSIFIED DRUG; 2,3,5,4'-TETRAHYDROXYSTILBENE-2-O-GLUCOSIDE; AROMATIC HYDROCARBON RECEPTOR; CYP3A11 PROTEIN, MOUSE; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; MEMBRANE PROTEIN; PREGNANE X RECEPTOR; STEROID RECEPTOR; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG SCREENING; FALLOPIA MULTIFLORA; INVESTIGATIVE PROCEDURES; LIVER; LIVER WEIGHT; LOW DRUG DOSE; MALE; MOUSE; MOUSE LIVER; NONHUMAN; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; WESTERN BLOTTING; ANIMAL; BODY WEIGHT; DRUG EFFECTS; GENETICS; METABOLISM; ORGAN SIZE;

MUS; POLYGONUM MULTIFLORUM;

ANIMALS; BODY WEIGHT; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME INHIBITORS; GLUCOSIDES; LIVER; MALE; MEMBRANE PROTEINS; MICE; ORGAN SIZE; PPAR ALPHA; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, STEROID; STILBENES;

EID: 84937115242     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2014.976779     Document Type: Article

References (35)

1. Angulo P. (2002). Nonalcoholic fatty liver disease. N Engl J Med 346:1221-31.
2. Bao B, Geng T, Cao Y, et al. (2012). Effects of schizonepetin on activity and mRNA expression of cytochrome P450 enzymes in rats. Int J Mol Sci 13:17006-18.
3. Barbier O, Fontaine C, Fruchart JC, Staels B. (2004). Genomic and non-genomic interactions of PPARα with xenobioticmetabolizing enzymes. Trends Endocrinol Metab 15:324-30.
4. Blomme EA, Yang Y, Waring JF. (2009). Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. Toxicol Lett 186:22-31.
5. Bolt M, Koos PH, Their R. (2003). The cytochrome P450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine. Int Arch Occup Environ Health 76:174-85.
6. Chang MJ, Xiao JH, Wang Y, et al. (2012). 2, 3, 5, 40 -Tetrahydroxystilbene-2-O-beta- D-glucoside improves gastrointestinal motility disorders in STZ-induced diabetic mice. PLoS One 7: e50291.
7. Denison MS, Nagy SR. (2003). Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 43:309-34.
8. Dixon J, Lane K, MacPhee I, Philips, B. (2014). Xenobiotic metabolism: the effect of acute kidney injury on non-renal drug clearance and hepatic drug metabolism. Int J Mol Sci 15:2538-53.
9. Gao N, Qi B, Liu FJ, et al. (2014). Inhibition of baicalin on metabolism of phenacetin, a probe of CYP1A2, in human liver microsomes and in rats. PLoS One 9:e89752.
10. Guengerich FP, Shimada T. (1998). Activation of procarcinogens by human cytochrome P450 enzymes. Mutat Res 400:201-13.
11. Huang Y, Zheng SL, Zhu HY, et al. (2014). Effects of aescin on cytochrome P450 enzymes in rats. J Ethnopharmacol 151:583-90.
12. Klein K, Zanger UM. (2013). Pharmacogenomics of cytochrome P450 3A4: recent progress toward the ''missing heritability'' problem. Front Genet 4:12-26.
13. Lu Y, Cederbaum AI. (2006). Enhancement by pyrazole of lipopoly-saccharide-induced liver injury in mice: role of cytochrome P450 2E1 and 2A5. Hepatology 44:263-74.
14. Lu Y, Cederbaum AI. (2008). CYP2E1 and oxidative liver injury by alcohol. Free Radic Biol Med 44:723-38.
15. Lu Y, Cederbaum AI. (2010). CYP2E1 potentiation of LPS and TNFa-induced hepatotoxicity by mechanisms involving enhanced oxidative and nitrosative stress, activation of MAP kinases, and mitochondrial dysfunction. Genes Nutr 5:149-67.
16. Nebert DW, Dalton TP. (2006). The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 6:947-60.
17. Pan YZ, Gao W, Yu AM. (2009). MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 37: 2112-17.
18. Rakhshandehroo M, Knoch B, Müller M, Kersten S. (2010). Peroxisome proliferator-activated receptor alpha target genes. PPAR Res 2010:612089.
19. Rendic S. (2002). Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83-448.
20. Sinz M, Kim S, Zhu Z, et al. (2006). Evaluation of 170 xenobiotics as transactivators of human pregnane x receptor (hpxr) and correlation to known cyp3a4 drug interactions. Curr Drug Metab 7:375-88.
21. Staudinger JL, Xu C, Biswas A, Mani S. (2011). Post-translational modification of pregnane x receptor. Pharmacol Res 64:4-10.
22. Synold TW, Dussault I, Forman BM. (2001). The orphan nuclear receptor sxr coordinately regulates drug metabolism and efflux. Nat Med 7:584-90.
23. Ueng YF, Jan WC, Lin LC, et al. (2002). The alkaloid rutaecarpine is a selective inhibitor of cytochrome P450 1A in mouse and human liver microsomes. Drug Metab Dispos 30:349-53.
24. Venkateswarlu K, Lamb DC, Kelly DE, et al. (1998). The N-terminal membrane domain of yeast NADPH-cytochrome P450 (CYP) oxidoreductase is not required for catalytic activity in sterol biosynthesis or in reconstitution of CYP activity. J Biol Chem 273:4492-6.
25. Wang QL, Wu Q, Tao YY, et al. (2011). Salvianolic acid B modulates the expression of drug-metabolizing enzymes in HepG2 cells. Hepatobiliary Pancreat Dis Int 10:502-8.
26. Wang T, Gu J, Wu PF, et al. (2009). Protection by tetrahydroxystilbene glucoside against cerebral ischemia: involvement of JNK, SIRT1, and NF-kappaB pathways and inhibition of intracellular ROS/RNS generation. Free Radic Biol Med 47:229-40.
27. Wang Z, Gorski JC, Hamman MA, et al. (2001). The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 70:317-26.
28. Xu RA, Xu ZS, Ge RS. (2014). Effects of hydroxysafflor yellow A on the activity and mRNA expression of four CYP isozymes in rats. J Ethnopharmacol 151:1141-6.
29. Yang Y, Wong SE, Lightstone FC. (2014). Understanding a substrate's product regioselectivity in a family of enzymes: a case study of acetaminophen binding in cytochrome P450s. PLoS One 9:e87058.
30. Yao W, Fan W, Huang C, et al. (2013). Proteomic analysis for anti-atherosclerotic effect of tetrahydroxystilbene glucoside in rats. Biomed Pharmacother 67:140-5.
31. Zanger UM, Turpeinen M, Klein K, Schwab M. (2008). Functional pharmacogenetics/genomicsof humancytochromesP450involved in drugbiotransformation. Anal Bioanal Chem 392:1093-108.
32. Zhang L, Yu S, Zhang R, et al. (2013). Tetrahydroxystilbene glucoside antagonizes age-related a -synuclein overexpression in the hippocampus of APP transgenic mouse model of Alzheimer's disease. Restor Neurol Neurosci 31:41-52.
33. (1-42)-injected rats and may be connected to synaptic changes in the hippocampus. Can J Physiol Pharmacol 90:1446-55.
34. Zhou SF, Koh HL, Gao YH, et al. (2004). Herbal bioactivation: the good, the bad and the ugly. Life Sci 74:935-68.
35. Zhou SF, Yang LP, Zhou ZW, et al. (2009). Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J 11:481-94.